865 related articles for article (PubMed ID: 19509147)
1. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
Soucy TA; Smith PG; Rolfe M
Clin Cancer Res; 2009 Jun; 15(12):3912-6. PubMed ID: 19509147
[TBL] [Abstract][Full Text] [Related]
2. Cullin-RING Ligases as attractive anti-cancer targets.
Zhao Y; Sun Y
Curr Pharm Des; 2013; 19(18):3215-25. PubMed ID: 23151137
[TBL] [Abstract][Full Text] [Related]
3. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.
Zhao Y; Morgan MA; Sun Y
Antioxid Redox Signal; 2014 Dec; 21(17):2383-400. PubMed ID: 24410571
[TBL] [Abstract][Full Text] [Related]
4. Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
Lamsoul I; Uttenweiler-Joseph S; Moog-Lutz C; Lutz PG
Biochimie; 2016 Mar; 122():339-47. PubMed ID: 26253693
[TBL] [Abstract][Full Text] [Related]
5. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
Soucy TA; Smith PG; Milhollen MA; Berger AJ; Gavin JM; Adhikari S; Brownell JE; Burke KE; Cardin DP; Critchley S; Cullis CA; Doucette A; Garnsey JJ; Gaulin JL; Gershman RE; Lublinsky AR; McDonald A; Mizutani H; Narayanan U; Olhava EJ; Peluso S; Rezaei M; Sintchak MD; Talreja T; Thomas MP; Traore T; Vyskocil S; Weatherhead GS; Yu J; Zhang J; Dick LR; Claiborne CF; Rolfe M; Bolen JB; Langston SP
Nature; 2009 Apr; 458(7239):732-6. PubMed ID: 19360080
[TBL] [Abstract][Full Text] [Related]
6. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
Flores-MartÃnez YA; Le-Trilling VTK; Trilling M
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
[TBL] [Abstract][Full Text] [Related]
7. Identification and application of NEDD8 E1 inhibitors.
Bruzzese FJ; Milhollen MA; Gavin JM; Josephine HR; Brownell JE
Methods Mol Biol; 2012; 832():577-88. PubMed ID: 22350913
[TBL] [Abstract][Full Text] [Related]
8. UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F.
Zhou W; Xu J; Tan M; Li H; Li H; Wei W; Sun Y
Mol Cell; 2018 Jun; 70(6):1008-1024.e6. PubMed ID: 29932898
[TBL] [Abstract][Full Text] [Related]
9. Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.
Nguyen HC; Wang W; Xiong Y
Subcell Biochem; 2017; 83():323-347. PubMed ID: 28271482
[TBL] [Abstract][Full Text] [Related]
10. Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases.
Ying J; Zhang M; Qiu X; Lu Y
Cancer Chemother Pharmacol; 2018 May; 81(5):797-808. PubMed ID: 29450620
[TBL] [Abstract][Full Text] [Related]
11. Changes in the ratio of free NEDD8 to ubiquitin triggers NEDDylation by ubiquitin enzymes.
Hjerpe R; Thomas Y; Chen J; Zemla A; Curran S; Shpiro N; Dick LR; Kurz T
Biochem J; 2012 Feb; 441(3):927-36. PubMed ID: 22004789
[TBL] [Abstract][Full Text] [Related]
12. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.
Nawrocki ST; Griffin P; Kelly KR; Carew JS
Expert Opin Investig Drugs; 2012 Oct; 21(10):1563-73. PubMed ID: 22799561
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
McMillin DW; Jacobs HM; Delmore JE; Buon L; Hunter ZR; Monrose V; Yu J; Smith PG; Richardson PG; Anderson KC; Treon SP; Kung AL; Mitsiades CS
Mol Cancer Ther; 2012 Apr; 11(4):942-51. PubMed ID: 22246439
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cullin RING ligases.
Hotton SK; Callis J
Annu Rev Plant Biol; 2008; 59():467-89. PubMed ID: 18444905
[TBL] [Abstract][Full Text] [Related]
15. NEDD8 and ubiquitin ligation by cullin-RING E3 ligases.
Baek K; Scott DC; Schulman BA
Curr Opin Struct Biol; 2021 Apr; 67():101-109. PubMed ID: 33160249
[TBL] [Abstract][Full Text] [Related]
16. Control of cullin-ring ubiquitin ligase activity by nedd8.
Deshaies RJ; Emberley ED; Saha A
Subcell Biochem; 2010; 54():41-56. PubMed ID: 21222272
[TBL] [Abstract][Full Text] [Related]
17. TRIAD1 and HHARI bind to and are activated by distinct neddylated Cullin-RING ligase complexes.
Kelsall IR; Duda DM; Olszewski JL; Hofmann K; Knebel A; Langevin F; Wood N; Wightman M; Schulman BA; Alpi AF
EMBO J; 2013 Oct; 32(21):2848-60. PubMed ID: 24076655
[TBL] [Abstract][Full Text] [Related]
18. E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification.
Huang DT; Ayrault O; Hunt HW; Taherbhoy AM; Duda DM; Scott DC; Borg LA; Neale G; Murray PJ; Roussel MF; Schulman BA
Mol Cell; 2009 Feb; 33(4):483-95. PubMed ID: 19250909
[TBL] [Abstract][Full Text] [Related]
19. Two Distinct Types of E3 Ligases Work in Unison to Regulate Substrate Ubiquitylation.
Scott DC; Rhee DY; Duda DM; Kelsall IR; Olszewski JL; Paulo JA; de Jong A; Ovaa H; Alpi AF; Harper JW; Schulman BA
Cell; 2016 Aug; 166(5):1198-1214.e24. PubMed ID: 27565346
[TBL] [Abstract][Full Text] [Related]
20. Targeting E3 ubiquitin ligases for cancer therapy.
Sun Y
Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
